Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Way of Life Sciences fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast. I'll now turn the call over to Kate Roush, Vice President of Corporate Affairs and Investor Relations. Please go ahead. Thank you, Sophie. And good morning to everyone on the call. Earlier this morning, we issued a press release outlining our fourth quarter and full year 2025 earnings updates. Joining me today with prepared remarks are Dr. Paul Bono, President and Chief Executive Officer, Dr. Chris Wright, Chief Medical Officer, and Kyle Moran, Chief Financial Officer. Dr. Eric Engelson, Chief Scientific Officer, will be available for questions after the call. The press release issued this morning is available on the investor section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul. Thanks, Kate. And good morning to everyone joining us on today's call. 2025 was a tremendous year for WAVE, marked by positive clinical data sets in obesity and AATD that further demonstrated the broad potential of our unique, differentiated RNAi and RNA editing capabilities. Entering 2026, we are building on the...